Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

Kranenburg, 2005, The KRas oncogene: past, present and future, Biochim Biophys Acta., 1756, 81

Raponi, 2008, KRAS mutations predict response to EGFR inhibitors, Curr Opin Pharmacol., 8, 413, 10.1016/j.coph.2008.06.006

Loriot, 2009, Are RAS mutations predictive markers of resistance to standard chemotherapy?, Nat Rev Clin Oncol., 6, 528, 10.1038/nrclinonc.2009.106

Capella, 1991, Frequency and spectrum of mutations at codons 12 and 13 of the C-K-ras gene in human tumors, Environ Health Perspect., 93, 125, 10.1289/ehp.9193125

Poorta, 2009, Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: etiopathogenic similarities, differences and paradoxes, Mutat Res., 682, 83, 10.1016/j.mrrev.2009.07.003

Andreyev, 1998, Kirsten ras mutations in patients with colorectal cancer: a multicenter “RASCAL” study, J Nat Cancer Inst., 90, 675, 10.1093/jnci/90.9.675

Siegfried, 1997, Prognostic value of specific KRAS mutations in lung adenocarcinoma, Cancer Epidemiol Biomarkers Prev., 6, 841

Hunt, 2002, Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens, Cancer Epidemiol Biomarkers Prev., 11, 1405

Cully, 2008, SnapShot: Ras signaling, Cell., 133, 1292, 10.1016/j.cell.2008.06.020

Kim, 2011, The BATTLE trial: personalizing therapy for lung cancer, Cancer Discov., 1, 44, 10.1158/2159-8274.CD-10-0010

Shames, 2006, A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies, PLoS Med., 3, e486, 10.1371/journal.pmed.0030486

Sullivan, 2010, Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling, Cancer Res., 70, 9937, 10.1158/0008-5472.CAN-10-0881

Sato, 2006, Multiple oncogenic changes (K-RAS[V12], p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells, Cancer Res., 66, 2116, 10.1158/0008-5472.CAN-05-2521

Vikis, 2007, EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity, Cancer Res., 67, 4665, 10.1158/0008-5472.CAN-07-0217

Pacold, 2000, Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma, Cell., 103, 931, 10.1016/S0092-8674(00)00196-3

Huang, 1998, Structural basis for the interaction of Ras with RalGDS, Nat Struct Biol., 5, 422, 10.1038/nsb0698-422

Phillips, 2005, Scalable molecular dynamics with NAMD, J Comput Chem., 26, 1781, 10.1002/jcc.20289

Gorfe, 2008, Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins, Structure., 16, 885, 10.1016/j.str.2008.03.009

Seeber, 2007, A program for efficient analysis of molecular dynamics simulations, Bioinformatics., 23, 2625, 10.1093/bioinformatics/btm378

Pierce, 2007, ZRANK: reranking protein docking predictions with an optimized energy function, Proteins., 67, 1078, 10.1002/prot.21373

Dunlop, 2009, Mammalian target of rapamycin 1: signaling inputs, substrates and feedback mechanisms, Cell Signal., 21, 827, 10.1016/j.cellsig.2009.01.012

Garassino, 2011, Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer, Ann Oncol., 22, 235, 10.1093/annonc/mdq680

Fan, 1997, KRas modulates the cell cycle via both positive and negative regulatory pathways, Oncogene., 14, 2595, 10.1038/sj.onc.1201105

Drosten, 2010, Genetic analysis of Ras signaling pathways in cell proliferation, migration, and survival, EMBO J., 29, 1091, 10.1038/emboj.2010.7

Hamad, 2002, Distinct requirements for Ras oncogenesis in human versus mouse cells, Genes Dev., 16, 2045, 10.1101/gad.993902

Tuveson, 2004, Endogenous oncogenic KRas (G12D) stimulates proliferation and widespread neoplastic and developmental defects, Cancer Cell., 5, 375, 10.1016/S1535-6108(04)00085-6

Floyd, 2005, Conditional expression of the mutant Ki-Ras G12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model, Carcinogenesis., 26, 2196, 10.1093/carcin/bgi190

Dance-Barnes, 2008, Effects of mutant human Ki-Ras (G12C) gene dosage on murine lung tumorgenesis and signaling to downstream effectors, Toxicol Appl Pharmacol., 231, 77, 10.1016/j.taap.2008.04.014

O’Reilly, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res., 66, 1500, 10.1158/0008-5472.CAN-05-2925